<DOC>
	<DOCNO>NCT02210000</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo control trial design confirm symptomatic effect camicinal treatment vs. placebo , gastroparesis symptom type 1 2 diabetic subject gastroparesis . The primary purpose study determine low-dose camicinal ( 25 milligram [ mg ] ) 12 week repeat administration improve gastroparesis symptom measure Gastrointestinal Cardinal Symptom Index - Daily Diary ( GCSI-DD ) approximately 120 subject type 1 2 diabetes mellitus ( DM ) document abnormally slow gastric empty symptom consistent gastroparesis . Subjects randomize 1:1 ratio receive either camicinal placebo . The study consist screening/baseline period 35 day , 12 week treatment period , 2-week post-treatment assessment symptom 14 day ( +/- 2 day ) post treatment safety follow-up visit .</brief_summary>
	<brief_title>A Study Evaluate Effect Camicinal Gastroparesis Symptoms Type 1 2 Diabetic Subjects With Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Type 1 2 diabetes mellitus ( acetylate hemoglobin A1 [ HbA1c ] &lt; =11.0 % ) Male female 18 80 year age , inclusive . Patient gastroparesis screening . A patient eligible one follow criterion meet : Gastric halftime empty &gt; upper limit normal determine Carbon13 radioisotope ( C13 ) oral breath test ; % C13dose recover &lt; low limit normal 90 120 minute Patient must report &gt; =3 month history relevant symptom gastroparesis ( e.g. , chronic postprandial fullness , early satiety , postprandial nausea ) . Patients mean daily score minimum 7 day indicate &gt; = mild ( 2 ) severity fullness/early satiety subscale assess use GCSIDD screening period prior randomization . A female patient eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] &gt; 40 milli international unit per milliliter [ mIU/mL ] , value consistent local laboratory standard value , confirmatory ) childbearing potential agrees use contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female patient must agree use contraception least 5 day follow last dose study medication . Body mass index ( BMI ) &gt; 18 &lt; =42.0 kilogram per meter square ( kg/m^2 ) ( inclusive ) . QTc &lt; 450 millisecond ( msec ) QTc &lt; 480 msec patient Bundle Branch Block base single average QTc value triplicate value obtain brief recording period . The QT correction formula ( Bazett 's , Fridericia 's , etc ) use determine inclusion discontinuation throughout study . Aspartate aminotransferase alanine aminotransferase &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Capable give write informed consent , include compliance requirement restriction list consent form . Patient acute severe gastroenteritis Patient gastric pacemaker Patient chronic enteral ( e.g. , feed tube ) parenteral feed Recent ( last 6 week ) history poor control diabetes e.g . hypoglycaemia require medical intervention , diabetic ketoacidosis , admission control diabetes complication diabetes Patient evidence severe cardiovascular autonomic neuropathy ( e.g . history recurrent syncope last 6 month ) Patient history eat disorder ( anorexia nervosa , binge eating , bulimia ) Use medication potentially influence upper gastrointestinal motility appetite least 1 week prior screening ( e.g. , prokinetic drug , macrolide antibiotic [ erythromycin ] , glucagonlike peptide1 [ GLP1 ] mimetics ) Patient intrapyloric botox injection . A patient would eligible botox treatment past ( &gt; 6 month previously ) repeat . Patient gastrectomy , major gastric surgical procedure evidence bowel obstruction stricture within previous 12 month Dosage concomitant medication stable least 3 week , except routine adjustment daily insulin treatment . Estimated ( measure ) glomerular filtration rate &lt; =30 mL/minute . Daily opiate use screening Use prohibit medication potentially influence upper gastrointestinal motility appetite , medication may interfere method measure gastric empty e.g. , prokinetic drug , macrolide antibiotic ( erythromycin , azithromycin ) , GLP1 mimetics , anticholinergic , chronic/regular use opiates History presence clinically significant gastrointestinal , hepatic renal disease ( include liver disease know hepatic biliary abnormality , exception Gilbert 's syndrome asymptomatic gallstone ) condition would opinion investigator medical monitor make subject unsuitable inclusion clinical study . Concurrent enrollment interventional study/ ( y ) involve novel ( i.e . unapproved experimental ) chemical biopharmaceutical entity . History sensitivity study medication , component thereof history drug allergy , opinion investigator GlaxoSmithKline Medical Monitor , contraindicate participation . Lactating Pregnant female determine positive serum urine human chorionic gonadotropin test ( first urine day ) screen prior dosing . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>repeat dose</keyword>
	<keyword>phase II</keyword>
	<keyword>GCSI-DD</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>gastroparesis</keyword>
	<keyword>type 1 type 2 diabetes mellitus</keyword>
	<keyword>camicinal</keyword>
	<keyword>GSK962040</keyword>
	<keyword>symptom</keyword>
	<keyword>gut motility</keyword>
</DOC>